Verónica Gómez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Verónica Gómez has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Beatrix Oroszi
National Laboratory for Health Security, Epidemiology and Surveillance Centre Semmelweis University Budapest Hungary
11 shared publications - Angela Mary Catherine Rose
EpiConcept, Paris, France
9 shared publications - Ausenda Machado
Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
9 shared publications - Jesús Castilla
Instituto de Salud Pública de Navarra—IdiSNA , Pamplona
9 shared publications - Ralf Dürrwald
Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre Robert Koch Institute Berlin Germany
8 shared publications Iván Martínez-Baz
Affiliation Instituto de Salud Pública de Navarra – IdiSNA – CIBERESP, Pamplona, Spain
7 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (9)
Influenza Vaccine Effectiveness Against Mild and Severe Outcomes: A Comparison Study in Portugal
Background: Influenza vaccination is an effective public health intervention to lessen influenza effect on healthcare and has been recommended to prevent severe outcomes. Previous studies present higher influenza vaccine effectiveness (IVE) estimates against primary care medically attended (outpatients) compared to hospitalised cases (inpatients). Inconsistencies in study designs may hinder comparisons of IVE in preventing mild (outpatient consultations) versus severe influenza (inpatient admissions). We aimed to compare IVE against mild and severe influenza within primary care and hospital networks in Portugal from 2015/16 to 2023/24. Methods: Using the test‐negative design, we analysed 3393 RT‐PCR‐tested patients with influenza‐like illness in outpatients or severe acute respiratory infection in inpatients. IVE was estimated using a generalised linear mixed model with fixed effects for sex, age category, comorbidities, month of symptom onset and random effects for season. For difference estimation, 95% confidence intervals (CI) were obtained through bootstrapping. Results: IVE was 40.4% (22.7; 54.0) for outpatients and 38.7% (17.6; 54.5) for inpatients. The 1.7% difference was not statistically significant (−22.0; 26.8). Subgroup analyses for individuals aged ≥ 65 years, patients with comorbidities and by influenza A subtype showed similar non‐significant differences, ranging from −1% to 17%. Conclusion: We found no statistically significant difference in IVE against mild or severe influenza infection. However, comparison across care settings should be interpreted cautiously, as patients differ in sociodemographic characteristics and comorbidity burden. Although limited sample size may reduce statistical power, the small magnitude of observed differences suggests that patients benefit from current vaccination strategies across care settings.
- 31 August 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (9)
Open AccessInfluenza Vaccine Effectiveness Against Mild and Severe Outcomes: A Comparison Study in Portugal
Background: Influenza vaccination is an effective public health intervention to lessen influenza effect on healthcare and has been recommended to prevent severe outcomes. Previous studies present higher influenza vaccine effectiveness (IVE) estimates against primary care medically attended (outpatients) compared to hospitalised cases (inpatients). Inconsistencies in study designs may hinder comparisons of IVE in preventing mild (outpatient consultations) versus severe influenza (inpatient admissions). We aimed to compare IVE against mild and severe influenza within primary care and hospital networks in Portugal from 2015/16 to 2023/24. Methods: Using the test‐negative design, we analysed 3393 RT‐PCR‐tested patients with influenza‐like illness in outpatients or severe acute respiratory infection in inpatients. IVE was estimated using a generalised linear mixed model with fixed effects for sex, age category, comorbidities, month of symptom onset and random effects for season. For difference estimation, 95% confidence intervals (CI) were obtained through bootstrapping. Results: IVE was 40.4% (22.7; 54.0) for outpatients and 38.7% (17.6; 54.5) for inpatients. The 1.7% difference was not statistically significant (−22.0; 26.8). Subgroup analyses for individuals aged ≥ 65 years, patients with comorbidities and by influenza A subtype showed similar non‐significant differences, ranging from −1% to 17%. Conclusion: We found no statistically significant difference in IVE against mild or severe influenza infection. However, comparison across care settings should be interpreted cautiously, as patients differ in sociodemographic characteristics and comorbidity burden. Although limited sample size may reduce statistical power, the small magnitude of observed differences suggests that patients benefit from current vaccination strategies across care settings.
- Open Access
- 27 August 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16–2024/25
1. Seasonal influenza remains a major cause of morbidity and mortality worldwide, particularly among older adults [1]. Individuals aged 65 years account for a substantial proportion of influenza-a...
- 27 August 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Open AccessAssociation between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16–2024/25
1. Seasonal influenza remains a major cause of morbidity and mortality worldwide, particularly among older adults [1]. Individuals aged 65 years account for a substantial proportion of influenza-a...
- Open Access
- 9 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0343988
Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24
Introduction: Genetic changes in COVID-19 variants/sublineages (VSLs) can reduce vaccine effectiveness (VE). Timely VSL-specific VE estimates are essential, but study-specific VSL identification by whole genome sequencing (the “gold standard”) is expensive and time-consuming. Alternatively, VSL-specific VE has been estimated from external sequencing data (VSL predominance period by proxy: PP). We propose two novel approaches for use in test-negative design (TND) studies to estimate VSL-specific VE when study-specific VSL identification is not possible. Methods: We demonstrate the variant category model (VCM) and the variant proportion model (VPM) approaches. Using data from a hospital-based TND study among adults ≥65 years, during the period of sequential predominance of XBB and BA.2.86 in 2023/24, we estimated the VE as (1-OR) x 100%. For the VCM, we used a binary variable categorising “most likely underlying sublineage” based on publicly available sequencing data. For the VPM, we used a continuous variable with values from 0 to 1 representing the weekly proportion of BA.2.86. We validated results using study-specific VSL identification from sequenced study data (SD) and the standard PP approach. Results: Overall, at 14–59 days post vaccination, VE point estimates against XBB were within ±3% absolute for the VE estimated using both models, with an equivalent standard PP validation. We could not validate using SD, as there were no vaccinated XBB cases. Against BA.2.86, VE was lower than against XBB, and the VCM and VPM results were within ±7% absolute of each other, with lowest validation results from SD but equivalent results from the PP. Conclusions: Both proposed approaches produced similar VE estimates to those from well-known methods. The VPM could also provide VE estimates when the validation techniques were limited by low sample size.
- 9 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0343988
Open AccessModelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24
Introduction: Genetic changes in COVID-19 variants/sublineages (VSLs) can reduce vaccine effectiveness (VE). Timely VSL-specific VE estimates are essential, but study-specific VSL identification by whole genome sequencing (the “gold standard”) is expensive and time-consuming. Alternatively, VSL-specific VE has been estimated from external sequencing data (VSL predominance period by proxy: PP). We propose two novel approaches for use in test-negative design (TND) studies to estimate VSL-specific VE when study-specific VSL identification is not possible. Methods: We demonstrate the variant category model (VCM) and the variant proportion model (VPM) approaches. Using data from a hospital-based TND study among adults ≥65 years, during the period of sequential predominance of XBB and BA.2.86 in 2023/24, we estimated the VE as (1-OR) x 100%. For the VCM, we used a binary variable categorising “most likely underlying sublineage” based on publicly available sequencing data. For the VPM, we used a continuous variable with values from 0 to 1 representing the weekly proportion of BA.2.86. We validated results using study-specific VSL identification from sequenced study data (SD) and the standard PP approach. Results: Overall, at 14–59 days post vaccination, VE point estimates against XBB were within ±3% absolute for the VE estimated using both models, with an equivalent standard PP validation. We could not validate using SD, as there were no vaccinated XBB cases. Against BA.2.86, VE was lower than against XBB, and the VCM and VPM results were within ±7% absolute of each other, with lowest validation results from SD but equivalent results from the PP. Conclusions: Both proposed approaches produced similar VE estimates to those from well-known methods. The VPM could also provide VE estimates when the validation techniques were limited by low sample size.
- Open Access
- 25 November 2025
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 19 (11) , e70191
COVID‐19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024–May 2025
We estimated COVID‐19 vaccine effectiveness (VE) against PCR‐confirmed SARS‐CoV‐2 hospitalization in patients ≥ 60 years with severe acute respiratory infection, using a multicenter, test‐negative, case–control study across seven sites in six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9980 controls (5024 vaccinated; 50%). VE was 42% (95% CI: 15; 61) 14–59 days post‐vaccination, 32% (95% CI: −1; 54) at 60–119 days, and 36% (95% CI: 2; 60) at 120–179 days, and no effect thereafter. Among adults aged 60–79 and ≥ 80 years, we observed moderate VE against COVID‐19 hospitalization for up to 2 and 4 months, respectively.
- 25 November 2025
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 19 (11) , e70191
Open AccessCOVID‐19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024–May 2025
We estimated COVID‐19 vaccine effectiveness (VE) against PCR‐confirmed SARS‐CoV‐2 hospitalization in patients ≥ 60 years with severe acute respiratory infection, using a multicenter, test‐negative, case–control study across seven sites in six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9980 controls (5024 vaccinated; 50%). VE was 42% (95% CI: 15; 61) 14–59 days post‐vaccination, 32% (95% CI: −1; 54) at 60–119 days, and 36% (95% CI: 2; 60) at 120–179 days, and no effect thereafter. Among adults aged 60–79 and ≥ 80 years, we observed moderate VE against COVID‐19 hospitalization for up to 2 and 4 months, respectively.
- Open Access
- 30 July 2025
- Published by Wiley
COVID-19 vaccine effectiveness against hospitalisation in older adults, VEBIS hospital network, Europe, September 2024--May 2025
We estimated COVID-19 vaccine effectiveness (VE) against PCR-confirmed SARS-CoV-2 hospitalisation in patients ≥60 years with severe acute respiratory infection, using a multicentre, test-negative case-control study across six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9 980 controls (5 024 vaccinated; 50%). VE was 42% (95%CI:15;61) 14–59 days post-vaccination, 32% (95%CI: -1;54) at 60–119 days, and 36% (95%CI: 2;60) at 120–179 days, and no effect thereafter. Among adults aged 60–79 and ≥80 years, we observed moderate VE against COVID-19 hospitalisation for up to 2 and 4 months, respectively.
- 30 July 2025
- Published by Wiley
Open AccessCOVID-19 vaccine effectiveness against hospitalisation in older adults, VEBIS hospital network, Europe, September 2024--May 2025
We estimated COVID-19 vaccine effectiveness (VE) against PCR-confirmed SARS-CoV-2 hospitalisation in patients ≥60 years with severe acute respiratory infection, using a multicentre, test-negative case-control study across six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9 980 controls (5 024 vaccinated; 50%). VE was 42% (95%CI:15;61) 14–59 days post-vaccination, 32% (95%CI: -1;54) at 60–119 days, and 36% (95%CI: 2;60) at 120–179 days, and no effect thereafter. Among adults aged 60–79 and ≥80 years, we observed moderate VE against COVID-19 hospitalisation for up to 2 and 4 months, respectively.
- Open Access
- 4 December 2024
- Published by Wiley
Effectiveness of the XBB.1.5 COVID-19 vaccines against SARS-CoV-2 hospitalisation among adults aged ≥65 years during the BA.2.86/JN.1 predominant period, VEBIS hospital study, Europe, November 2023 to May 2024
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14–59 days, 34% at 60–119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post vaccination.
- 4 December 2024
- Published by Wiley
Open AccessEffectiveness of the XBB.1.5 COVID-19 vaccines against SARS-CoV-2 hospitalisation among adults aged ≥65 years during the BA.2.86/JN.1 predominant period, VEBIS hospital study, Europe, November 2023 to May 2024
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14–59 days, 34% at 60–119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post vaccination.
- Open Access
- 10 November 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (11) , e70009
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.
- 10 November 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (11) , e70009
Open AccessEffectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.
- Open Access
- 15 August 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (8) , e13360
Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024
We conducted a multicentre test‐negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID‐19 vaccines conferred protection against COVID‐19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
- 15 August 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (8) , e13360
Open AccessEarly COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024
We conducted a multicentre test‐negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID‐19 vaccines conferred protection against COVID‐19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
- Open Access
- 16 July 2024
- Published by Wiley
Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in older adults during the JN.1 lineage-predominant period, European VEBIS primary care multicentre study, 20 November 2023--1 March 2024
Not-yet-known not-yet-known not-yet-known unknown We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥65 years during the 2023/24 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: -11–48) and 5% (95% CI: -92–56) among those with symptom onset 1–5 , 6–11, and ≥12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.
- 16 July 2024
- Published by Wiley
Open AccessEffectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in older adults during the JN.1 lineage-predominant period, European VEBIS primary care multicentre study, 20 November 2023--1 March 2024
Not-yet-known not-yet-known not-yet-known unknown We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥65 years during the 2023/24 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: -11–48) and 5% (95% CI: -92–56) among those with symptom onset 1–5 , 6–11, and ≥12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.
- Open Access
- 19 May 2024
- Published by Wiley
Early COVID-19 XBB.1.5 vaccine effectiveness against hospitalisation among adults targeted for vaccination, VEBIS hospital network, Europe, October 2023--January 2024
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 48% overall, ranging between 68% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE >70% in older adults (≥65 years) up to 1 month post vaccination.
- 19 May 2024
- Published by Wiley
Open AccessEarly COVID-19 XBB.1.5 vaccine effectiveness against hospitalisation among adults targeted for vaccination, VEBIS hospital network, Europe, October 2023--January 2024
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 48% overall, ranging between 68% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE >70% in older adults (≥65 years) up to 1 month post vaccination.